-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Through so many cancer scares, I’m trying to live in gratitude that my sister’s time is not now.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3The Long and Winding Road Leading to My Non-Hodgkin Lymphoma - 8 day(s) ago
The day I found out I had cancer, my wife and I thought I would just be going in for a scan.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 23FDA Approves First Ever BTK Inhibitor to Treat Lymphoma Subtype | Leukemia and Lymphoma Society - 10 day(s) ago
FDA Approves First Ever BTK Inhibitor to Treat Lymphoma Subtype > Page Components
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0Columvi Plus GemOx May Improve Survival in R/R DLBCL - 14 day(s) ago
The phase 3 STARGLO study met its primary endpoint of improved overall survival, according to Columvi’s manufacturer, Genetech.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3Spotlight On Hodgkin Lymphoma | Leukemia and Lymphoma Society - 19 day(s) ago
Join us for a free webinar covering the latest information for patients and caregivers. To register by phone, call (855) 709-3274. Topics Covered We invite you to learn more about: Treatment advances for Hogkin lymphoma Side-effect management Treatment options for relapse/refractory patients Monitoring for long term and late effects The importance of discussing quality-of-life issues with your healthcare team Speaker Jeremy Abramson, MD Director, Jon and Jo Ann Hagler Center for Lymphoma Massachusetts General Hospital Cancer Center Associate Professor of Medicine Harvard Medical School Boston, MA Submit a question for Dr. Abramson to answer during the Q&A session. Program Support Support for this program provided by The Leukemia & Lymphoma Society . < Back to Webcasts
Source: www.lls.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2New CAR-T Therapy Safe and Efficacious for Non-Hodgkin Lymphoma - 21 day(s) ago
The novel CAR-T cell therapy, HR001, showed promise in a recent trial of patients with relapsed or refractory non-Hodgkin lymphoma.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 3Finding Cancer Cures at Any and All Costs - 25 day(s) ago
It was disconcerting to me when my oncologist was unsure about the treatment he was giving me and knew what the next would be without giving the first a chance.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
-
Mashup Score: 14Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma - 1 month(s) ago
Hoang et al. shows that DNA methyltransferase 3A (DNMT3A) regulates cellular energy production in mitochondria and contributes to the resistance of mantle cell lymphoma to ibrutinib, an inhibitor of Bruton tyrosine kinase. Targeting DNMT3A with low-dose decitabine is a potential therapeutic strategy to overcome ibrutinib resistance.
Source: www.cell.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1My Food Choice Journey After Cancer - 2 month(s) ago
For 14 years, I’ve been dealing with small lymphocytic lymphoma, and want to maintain a healthier diet.
Source: www.curetoday.comCategories: General Medicine News, NursingTweet
A 3-year follow-up of the ZUMA-5 trial underscores axi-cel's sustained efficacy in treating r/r indolent non-Hodgkin #lymphoma, with robust overall response rates and manageable safety. Keep reading: https://t.co/kB7bB4tUcs https://t.co/Q1eJzvYfh0